Sustained activation of fibroblast transforming growth Factor-β/Smad signaling in a murine model of scleroderma

被引:91
|
作者
Takagawa, S
Lakos, G
Mori, Y
Yamamoto, T
Nishioka, K
Varga, J
机构
[1] Univ Illinois, Rheumatol Sect, Coll Med, Chicago, IL 60607 USA
[2] Tokyo Med & Dent Univ, Dept Dermatol & Environm Immunodermatol, Grad Sch, Tokyo, Japan
关键词
bleomycin; murine scleroderma; Smad; transforming growth factor-beta;
D O I
10.1046/j.1523-1747.2003.12308.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Transforming growth factor-beta is responsible for triggering a cascade of events leading to fibrosis in scleroderma. The Smads are intracellular signal transducers recently shown to mediate fibroblast activation and other profibrotic responses elicited by transforming growth factor-betain vitro . To understand better the involvement of Smads in the pathogenesis of fibrosis, we ex-amined Smad expression and activation in situ in a murine model of scleroderma. Bleomycin injections induced striking dermal infiltration with macrophages by 3 d, and progressive fibrosis by 2 wk. Infiltrating macrophages and resident fibroblasts expressed Smad3, the positive mediator for transforming growth factor-beta responses. Importantly, in bleomycin-injected skin, fibroblasts showed predominantly nuclear localization of Smad3 and intense staining for phospho-Smad2/3. Furthermore, phosphorylated Smad2/3 in fibroblasts was detected even after the resolution of inflammation. Expression of Smad7, the endogenous inhibitor of transforming growth factor-beta/Smad signaling, was strongly induced in dermal cells by transforming growth factor-beta, but not by bleomycin injections. Collectively, these results indicate that bleomycin-induced murine scleroderma is associated with rapid and sustained induction of transforming growth factor-beta/Smad signaling in resident dermal fibroblasts. Despite apparent activation of the intracellular transforming growth factor-beta signaling pathway in the lesional dermis, the expression of transforming growth factor-beta-inducible Smad7 was not upregulated. In light of the critical function of Smad7 as an endogenous inhibitor of Smad signaling that restricts the duration and magnitude of transforming growth factor-beta responses, and as a mediator of apoptosis, relative Smad7 deficiency observed in the present studies may account for sustained activation of transforming growth factor-beta/Smad signaling in lesional tissues. These findings raise the possibility that Smads plays an important part in the pathogenesis of fibrosis, and may therefore represent targets for selective anti-fibrotic interventions.
引用
收藏
页码:41 / 50
页数:10
相关论文
共 50 条
  • [41] The roles of transforming growth factor-β and Smad3 signaling in adipocyte differentiation and obesity
    Tsurutani, Yuya
    Fujimoto, Masaki
    Takemoto, Minoru
    Irisuna, Hiroki
    Koshizaka, Masaya
    Onishi, Shunichiro
    Ishikawa, Takahiro
    Mezawa, Morito
    He, Peng
    Honjo, Satoshi
    Maezawa, Yoshiro
    Saito, Yasushi
    Yokote, Koutaro
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2011, 407 (01) : 68 - 73
  • [42] The transforming growth factor-β/SMAD signaling pathway is present and functional in human mesangial cells
    Poncelet, AC
    de Caestecker, MP
    Schnaper, HW
    KIDNEY INTERNATIONAL, 1999, 56 (04) : 1354 - 1365
  • [43] Human BAMBI Cooperates with Smad7 to Inhibit Transforming Growth Factor-β Signaling
    Yan, Xiaohua
    Lin, Zhenghong
    Chen, Feng
    Zhao, Xingang
    Chen, Hua
    Ning, Yuanheng
    Chen, Ye-Guang
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (44) : 30097 - 30104
  • [44] Mammalian transforming growth factor-βs:: Smad signaling and physio-pathological roles
    Javelaud, D
    Mauviel, A
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2004, 36 (07): : 1161 - 1165
  • [45] Activation of the Transforming Growth Factor-β/Activin Signaling Pathway in Human Atherosclerosis
    Oklu, Rahmi
    Hesketh, Robin
    Wicky, Stephan
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (11) : E293 - E293
  • [46] Transforming growth factor-β and Smad signalling in kidney diseases
    Wang, WS
    Koka, V
    Lan, HY
    NEPHROLOGY, 2005, 10 (01) : 48 - 56
  • [47] Transforming growth factor-β/Smad signalling in diabetic nephropathy
    Lan, Hui Yao
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2012, 39 (08): : 731 - 738
  • [48] Glucocorticoid receptor inhibits transforming growth factor-β signaling by directly targeting the transcriptional activation function of Smad3
    Song, CZ
    Tian, X
    Gelehrter, TD
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (21) : 11776 - 11781
  • [49] Inhibitory Effects of Resveratrol on Airway Remodeling by Transforming Growth Factor-β/Smad Signaling Pathway in Chronic Asthma Model
    Lee, Hwa Young
    Kim, In Kyoung
    Yoon, Hyoung Kyu
    Kwon, Soon Suk
    Rhee, Chin Kook
    Lee, Sook Young
    ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, 2017, 9 (01) : 25 - 34
  • [50] CTRP3 attenuates hepatic stellate cell activation through transforming growth factor-β/Smad signaling pathway
    Cheng, Chuantao
    Yu, Shuo
    Kong, Ran
    Yuan, Qinggong
    Ma, Yuefeng
    Yang, Wenbin
    Cao, Gang
    Xie, Liyi
    BIOMEDICINE & PHARMACOTHERAPY, 2017, 89 : 1387 - 1391